×
About 6,868 results

ALLMedicine™ Unstable Angina Center

Research & Reviews  2,757 results

Early management of unstable angina and non-ST segment elevation myocardial infarction:...
https://doi.org/10.1136/bmj.m4953
BMJ (Clinical Research Ed.);

Jan 19th, 2021 - Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance.|2021||

Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagul...
https://doi.org/10.21037/apm-20-1728
Annals of Palliative Medicine; Yan XQ, Zhang C et. al.

Jan 14th, 2021 - It has been estimated that nearly one-fifth post-percutaneous coronary intervention (PCI) patients treated with clopidogrel continued to have recurrent thrombotic events, which implied the limitation of "one-size-fits all" strategy for antiplatele...

Differential Vascular Responses to New-Generation Drug-Eluting Stenting According to Cl...
https://doi.org/10.1177/0003319720980607
Angiology Lee SJ, Hong SJ et. al.

Dec 21st, 2020 - We evaluated early vascular responses after new-generation drug-eluting stent (DES) implantation. From 2 randomized trials, we identified 471 patients (138 patients with acute myocardial infarction [AMI] vs 333 patients with stable angina or unsta...

Acute Chest Pain in Adults: Outpatient Evaluation.
https://www.ncbi.nlm.nih.gov/pubmed/33320506
American Family Physician; McConaghy JR, Sharma M et. al.

Dec 15th, 2020 - Approximately 1% of primary care office visits are for chest pain, and 2% to 4% of these patients will have unstable angina or myocardial infarction. Initial evaluation is based on determining whether the patient needs to be referred to a higher l...

The Genetic Variants -717T>C (rs2794521), 1444G>A (rs1130864), and 1846 C > T (rs1205) ...
https://doi.org/10.1089/met.2020.0080
Metabolic Syndrome and Related Disorders; Reynoso-Villalpando GL, Casillas-Muñoz FA et. al.

Dec 9th, 2020 - Background: C-reactive protein (CRP) is involved in inflammatory pathways that are associated with the onset and progression of type 2 diabetes mellitus (T2DM) as well as an increased risk of an acute coronary syndrome (ACS). This research aimed t...

see more →

Guidelines  27 results

Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP
https://www.aafp.org/afp/2019/0615/od2.html
American Family Physician;

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomi...

FDA Approves Praluent® (Alirocumab) To Prevent Heart Attack, Stroke And Unstable Angina Requiring Hospitalization
https://investor.regeneron.com/news-releases/news-release-details/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke

Apr 25th, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization...

Reduction Of Type 1 And Type 2 Myocardial Infarctions In Patients Treated With Alirocumab: Insights From The Odyssey Trial
http://www.onlinejacc.org/content/73/9_Supplement_1/4
White,H.,et al

Feb 28th, 2019 - LDL cholesterol (LDL-C) reduction with statins and PCSK9 inhibitors reduces risk of myocardial infarction (MI), but effects on specific types of MI are unknown. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab (ALI) with placebo (PBO) in 1...

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
http://www.onlinejacc.org/content/early/2019/03/21/j.jacc.2019.02.032
Bhatt,D.,et al

Feb 28th, 2019 - Background In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These patients are at risk for not only fi...

2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Manage...
http://www.onlinejacc.org/content/64/18/1929
Stephan D. Fihn

Oct 31st, 2014 - These guidelines are intended to apply to adult patients with stable known or suspected ischemic heart disease (IHD), including those with new-onset chest pain (i. e.

see more →

Drugs  329 results see all →

Clinicaltrials.gov  3,379 results

Early management of unstable angina and non-ST segment elevation myocardial infarction:...
https://doi.org/10.1136/bmj.m4953
BMJ (Clinical Research Ed.);

Jan 19th, 2021 - Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance.|2021||

Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagul...
https://doi.org/10.21037/apm-20-1728
Annals of Palliative Medicine; Yan XQ, Zhang C et. al.

Jan 14th, 2021 - It has been estimated that nearly one-fifth post-percutaneous coronary intervention (PCI) patients treated with clopidogrel continued to have recurrent thrombotic events, which implied the limitation of "one-size-fits all" strategy for antiplatele...

Prasugrel - prasugrel tablet, film coated-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04e7e0e8-2199-438f-83db-6b8f0f219b99

Jan 12th, 2021 - Prasugrel is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina...

Enoxaparin sodium - enoxaparin sodium injection-NorthStar Rx LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32f8d292-0dda-4931-81ea-ba47e23edf61

Dec 30th, 2020 - Enoxaparin Sodium Injection is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mob...

Clopidogrel - clopidogrel tablet-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d010775-1160-4b2e-a928-563a02edd191

Dec 27th, 2020 - Clopidogrel is a P2Y12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets have been shown to reduce t...

see more →

News  375 results

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.staging.medscape.com/viewarticle/933211

Jun 29th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.medscape.com/viewarticle/933211

Jun 29th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Has NICE Got It Wrong on Acute Coronary Syndromes?
https://www.staging.medscape.com/viewarticle/925473

Feb 20th, 2020 - This transcript has been edited for clarity. My name is Mamas Mamas. I'm professor of cardiology based at Keele University. So, today we're going to talk about The National Institute for Health and Care Excellence (NICE) consultation document for ...

Has NICE Got It Wrong on Acute Coronary Syndromes?
https://www.medscape.com/viewarticle/925473

Feb 20th, 2020 - This transcript has been edited for clarity. My name is Mamas Mamas. I'm professor of cardiology based at Keele University. So, today we're going to talk about The National Institute for Health and Care Excellence (NICE) consultation document for ...

The ISCHEMIA Trial -- Cardiology Changes Today
https://www.staging.medscape.com/viewarticle/921464

Nov 16th, 2019 - To Bernard Lown, MD: Sir, you are no longer a maverick. We should have listened to you. It took over 40 years, but today, at the American Heart Association (AHA) Scientific Sessions 2019, we learned that you were right to stop referring "most pati...

see more →

Patient Education  1 results see all →